Myricetin

ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute

Retrieved on: 
Tuesday, November 8, 2022
PCR, Medical physics, Research, Department, Gene, Dana–Farber Cancer Institute, Nature, LB-1, Radiation therapy, Company, Industry, Marketing, Dana, Dietary supplement, Environment, SEC, Cancer, Polymerase chain reaction, Acquisition, RT-PCR, COVID-19, Chromosome, CLIA, Private Securities Litigation Reform Act, Inherited disorders of trafficking, Prophase, Nasdaq, Vegetable, Linebacker, Polyphenol, Dementia, Harvard Medical School, Media relations, FDM, Nano, PIM, Toxicity, Growth, Memory, Central nervous system, Food, Trial of the century, GLOBE, Genomics, University, TK, Laboratory, OTC, Severe acute respiratory syndrome coronavirus 2, Labs, Risk, Nebula Genomics, COVID-19 testing, DNA, NASDAQ, Nano Letters, Publication, Myricetin, Inflammation, Pharmaceutical industry, Medical device, Medicinal plants, MD, Brigham

This collaboration provides for year 1 and year 2 research plans and will examine the tumoricidal effects of the flavonoid/polyphenol.

Key Points: 
  • This collaboration provides for year 1 and year 2 research plans and will examine the tumoricidal effects of the flavonoid/polyphenol.
  • ProPhase Labs is eager to explore new avenues for scientific discovery with these talented scientists as we pursue novel pathways for cancer treatment.
  • ProPhase BioPharma, Inc. (PBIO), a wholly owned subsidiary of ProPhase, was formed for the licensing, development and commercialization of novel drugs and compounds.
  • The company is collaborating with the Dana Farber Cancer Institute to develop LB-1 as a cancer co-therapy.

Impact BioMedical’s Proprietary Equivir Compound to Treat Viral Infection Receives Clean Patentability Report from World Intellectual Property Organization’s ISA Division

Retrieved on: 
Thursday, March 3, 2022
Risk, United Nations, Myricetin, DSS, IPO, EIS, Infection, Leadership, EVD, Rhinovirus, SARS, Virus, ISA, World, Patent, Health, Quality of life, International, Invention, FDA, Solution, Growth, LLC, Epidemic Intelligence Service, NYSE, Patentability, Renewable energy, Biomedicine, Degenerative disease, WIPO, Polyphenol, EHF, Ebola, GRAS, Acquisition, CEO, World Intellectual Property Organization, Â, Intellectual property, R, USPTO, Drug discovery, World Health Organization, First Nations in Ontario, Human, GLOBE, Vaccine, 3D printing, Pharmaceutical industry

The receipt of this clean patentability report for Equivirs international patent application is demonstrative of our desire to make Impact Biomedicals antiviral innovations available to protect people worldwide, said Frank.

Key Points: 
  • The receipt of this clean patentability report for Equivirs international patent application is demonstrative of our desire to make Impact Biomedicals antiviral innovations available to protect people worldwide, said Frank.
  • Equivir is believed to block the entry of virus to host cells and thereby prevent infection and replication in host cells.
  • It is hoped that Equivir can be used as a deployable strategic defense for a broad spectrum of viral infections.
  • Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades.